Cascadian Therapeutics Inc (NASDAQ:CASC) was the recipient of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 665,213 shares, a drop of 29.3% from the February 15th total of 941,371 shares. Based on an average trading volume of 656,707 shares, the short-interest ratio is currently 1.0 days.

A number of institutional investors have recently modified their holdings of CASC. Teachers Advisors LLC purchased a new position in Cascadian Therapeutics in the 2nd quarter valued at about $252,000. TIAA CREF Investment Management LLC purchased a new position in Cascadian Therapeutics in the 2nd quarter valued at about $347,000. New York State Common Retirement Fund purchased a new position in Cascadian Therapeutics in the 2nd quarter valued at about $136,000. Northern Trust Corp lifted its stake in Cascadian Therapeutics by 415.5% in the 2nd quarter. Northern Trust Corp now owns 382,469 shares of the biopharmaceutical company’s stock valued at $1,420,000 after buying an additional 308,270 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Cascadian Therapeutics by 24.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,767,681 shares of the biopharmaceutical company’s stock valued at $6,567,000 after buying an additional 343,838 shares in the last quarter. 81.38% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

CASC has been the topic of a number of analyst reports. BidaskClub cut Cascadian Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, March 7th. Cantor Fitzgerald set a $10.00 target price on Cascadian Therapeutics and gave the company a “hold” rating in a research report on Friday, March 9th. Raymond James Financial cut Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 31st. ValuEngine upgraded Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 31st. Finally, Zacks Investment Research cut Cascadian Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Cascadian Therapeutics has an average rating of “Hold” and a consensus price target of $6.17.

Cascadian Therapeutics (NASDAQ:CASC) opened at $10.02 on Thursday. The firm has a market cap of $506.61, a PE ratio of -7.48 and a beta of 3.79. Cascadian Therapeutics has a 12 month low of $3.18 and a 12 month high of $10.21.

WARNING: “Short Interest in Cascadian Therapeutics Inc (CASC) Declines By 29.3%” was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2018/03/15/short-interest-in-cascadian-therapeutics-inc-casc-declines-by-29-3.html.

About Cascadian Therapeutics

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.